McKesson Co. (NYSE:MCK) Forecasted to Earn Q2 2025 Earnings of $7.45 Per Share

McKesson Co. (NYSE:MCK) – Investment analysts at Leerink Partnrs increased their Q2 2025 earnings estimates for shares of McKesson in a research report issued to clients and investors on Monday, April 22nd. Leerink Partnrs analyst M. Cherny now expects that the company will post earnings of $7.45 per share for the quarter, up from their previous estimate of $7.36. Leerink Partnrs currently has a “Outperform” rating on the stock. The consensus estimate for McKesson’s current full-year earnings is $27.59 per share. Leerink Partnrs also issued estimates for McKesson’s FY2025 earnings at $31.37 EPS.

A number of other research firms have also recently commented on MCK. Argus upped their target price on shares of McKesson from $510.00 to $570.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Morgan Stanley upped their price objective on shares of McKesson from $522.00 to $548.00 and gave the stock an “overweight” rating in a report on Monday, April 15th. SVB Leerink assumed coverage on McKesson in a research report on Monday, February 26th. They issued an “outperform” rating and a $600.00 target price on the stock. Barclays initiated coverage on McKesson in a research note on Wednesday, January 3rd. They set an “overweight” rating and a $537.00 price target on the stock. Finally, Citigroup boosted their price objective on McKesson from $530.00 to $575.00 and gave the company a “buy” rating in a report on Thursday, February 8th. Two research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, McKesson has an average rating of “Moderate Buy” and an average price target of $533.50.

McKesson Stock Up 0.6 %

NYSE:MCK opened at $527.79 on Tuesday. The company has a market capitalization of $69.36 billion, a P/E ratio of 23.91, a P/E/G ratio of 1.42 and a beta of 0.45. McKesson has a 52 week low of $352.34 and a 52 week high of $543.00. The stock’s fifty day moving average is $525.58 and its two-hundred day moving average is $487.54.

McKesson (NYSE:MCK) last announced its quarterly earnings results on Wednesday, February 7th. The company reported $7.74 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $7.05 by $0.69. McKesson had a net margin of 0.99% and a negative return on equity of 262.63%. The business had revenue of $80.90 billion during the quarter, compared to the consensus estimate of $77.93 billion. During the same quarter last year, the firm earned $6.90 EPS. The business’s revenue was up 14.8% compared to the same quarter last year.

McKesson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, April 1st. Investors of record on Friday, March 1st were paid a dividend of $0.62 per share. The ex-dividend date of this dividend was Thursday, February 29th. This represents a $2.48 dividend on an annualized basis and a dividend yield of 0.47%. McKesson’s payout ratio is currently 11.24%.

Insider Activity at McKesson

In other McKesson news, CEO Brian S. Tyler sold 3,473 shares of the firm’s stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $524.55, for a total transaction of $1,821,762.15. Following the sale, the chief executive officer now owns 43,445 shares of the company’s stock, valued at $22,789,074.75. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other McKesson news, EVP Leann B. Smith sold 186 shares of the company’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $496.00, for a total transaction of $92,256.00. Following the completion of the sale, the executive vice president now directly owns 1,511 shares of the company’s stock, valued at approximately $749,456. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Brian S. Tyler sold 3,473 shares of McKesson stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $524.55, for a total value of $1,821,762.15. Following the completion of the transaction, the chief executive officer now owns 43,445 shares in the company, valued at $22,789,074.75. The disclosure for this sale can be found here. 0.21% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On McKesson

Several hedge funds have recently modified their holdings of MCK. Norges Bank acquired a new stake in shares of McKesson in the 4th quarter worth $1,024,140,000. International Assets Investment Management LLC increased its position in shares of McKesson by 1,044.5% in the fourth quarter. International Assets Investment Management LLC now owns 821,262 shares of the company’s stock valued at $380,228,000 after buying an additional 749,504 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in shares of McKesson by 16.0% in the third quarter. Massachusetts Financial Services Co. MA now owns 5,148,794 shares of the company’s stock valued at $2,238,953,000 after purchasing an additional 708,438 shares in the last quarter. TD Asset Management Inc raised its position in shares of McKesson by 202.8% during the 4th quarter. TD Asset Management Inc now owns 602,138 shares of the company’s stock worth $278,778,000 after purchasing an additional 403,312 shares during the last quarter. Finally, Morgan Stanley lifted its stake in McKesson by 14.0% in the 3rd quarter. Morgan Stanley now owns 2,398,380 shares of the company’s stock valued at $1,042,937,000 after buying an additional 294,832 shares in the last quarter. 85.07% of the stock is owned by institutional investors and hedge funds.

About McKesson

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.